SCHEMBL7120639

SCHEMBL7120639

CC(=O)c1cccc(Sc2ccc(C(=O)N[C@@H]3C[C@H]4CC[C@@H]3N4)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.43
EZH2 Q15910 1/20 0.41
HPGD P15428 2/20 0.39
ALDH1A1 P00352 1/20 0.39
SMYD3 Q9H7B4 1/20 0.39
LMNA P02545 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CREBBP Q92793 1/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A3 Q01959 2/20 0.36
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
HTR3A P46098 1/20 0.35
HTR3D Q70Z44 1/20 0.35
HTR3C Q8WXA8 1/20 0.35
CCR2 P41597 1/20 0.35
TRPV1 Q8NER1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7116048 0.90 HPGD (0.46) CHRNA7EZH2HPGDALDH1A1LMNA
SCHEMBL7124028 0.90 CHRNA7 (0.43) CHRNA7EZH2SLC6A2SLC6A4SLC6A3
SCHEMBL7116046 0.89 CHRNA7 (0.43) CHRNA7EZH2ALDH1A1SMYD3
SCHEMBL7121781 0.87 CHRNA7 (0.44) CHRNA7EZH2
SCHEMBL7127524 0.87 CHRNA7 (0.55) CHRNA7EZH2HPGDALDH1A1HTR3E
SCHEMBL7115037 0.87 CHRNA7 (0.38) CHRNA7EZH2HPGDALDH1A1SMYD3
SCHEMBL7127459 0.86 CHRNA7 (0.43) CHRNA7EZH2L3MBTL1TRPV1
SCHEMBL7125274 0.86 CHRNA7 (0.43) CHRNA7EZH2SLC6A2SLC6A4SLC6A3
SCHEMBL7125285 0.86 CHRNA7 (0.40) CHRNA7EZH2LMNASLC6A2SLC6A4
SCHEMBL7121838 0.86 MTNR1A (0.45) CHRNA7EZH2ALDH1A1SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US claimed
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease CYP7B1, UGT2B7, CYP1B1 CHRNA7 397/4885EZH2 462/4885HPGD 1941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.